'In­dus­tri­al­iz­ing the pro­duc­tion of cell­s': An­oth­er iP­SC play­er joins the quest for off-the-shelf cell ther­a­pies

Sci­en­tists have been af­ter the “Holy Grail” of cell ther­a­py — an off-the-shelf prod­uct — for years. Notch Ther­a­peu­tics is now join­ing the quest with a tech plat­form it says can in­dus­tri­al­ize the pro­duc­tion of cells. And on Wednes­day, it un­veiled a $85 mil­lion Se­ries A to get go­ing.

Notch was found­ed in 2018 by Juan Car­los Zúñi­ga-Pflück­er and Pe­ter Zand­stra, but “re­al­ly kicked off” in late 2019 when it signed a deal with Al­lo­gene to re­search al­lo­gene­ic cell ther­a­py can­di­dates, CEO David Main said. The nascent biotech got $10 mil­lion up­front, and stands to earn up to an­oth­er $294.2 mil­lion in mile­stones.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER